Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Quality, compliance and lifecycle regulatory services / Medtech & IVD quality-system implementation and compliance audit support

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Medtech & IVD quality-system implementation and compliance audit support

Outsourced build-out and remediation of ISO 13485 / EU MDR Chapter II / FDA QMSR (21 CFR 820) quality management systems for medical-device and in-vitro-diagnostic manufacturers, including documentation, procedure authoring, internal-audit preparation and notified-body or regulatory inspection readiness. Buyer is the device or IVD manufacturer; the job is to make the quality system inspection-ready and certificate-able; the trigger is a regulatory deadline, an audit finding, or entry into a new market.

Market size
$735M
$735M ($630M–$840M) · 2024 · Proxy
Growth
+6.5%
$1.1B by 2031
Attractiveness
— /100
for B2B sellers
Evidence
Low confidence
1 source · Proxy
Level
Niche
Segmented by
Customer type
Buyers
Medical-device and in-vitro-diagnostic manufacturers (typically 50–2,000 employees, EU- and US-selling)
Buying centre
VP/Head of Quality (owner), Head of Regulatory Affairs (co-approver), COO or plant/site head (budget), with the notified-body or FDA-facing relationship
Buying triggers
  • EU MDR transition and re-certification deadlines for legacy devices
  • FDA QMSR (21 CFR 820) harmonisation and inspection-readiness cycle
  • Notified-body audit findings, major non-conformities or certificate suspension
  • New market entry (US, EU, Japan, Brazil) requiring a compliant QMS
Pains
  • Fragmented, paper-based quality systems that fail audit sampling
  • Notified-body and FDA audit findings that delay market access
  • Internal audit and CAPA workload competing with engineering capacity
  • Quality-system documentation that does not map to MDR/21 CFR 820 clauses
Scores (1–5)
Pain intensity—
Purchasing power—
Reachability—
Growth—

How this was sized

$735M ($630M–$840M) · 2024 · Proxy

Anchor: medtech device regulatory-affairs outsourcing of USD 2.1B in 2024, forecast USD 8.1B by 2031 at 6–7% p.a. [2]. Quality-system implementation plus compliance-audit support assumed to be 30–40% of that device regulatory outsourcing pool (USD 630–840M; midpoint USD 735M), with the balance covering submissions, writing and product registration. Forecast applies the published 6.5% CAGR to the 2024 base: 735 x 1.065^7 = USD 1,146M, rounded to USD 1,150M in 2031. Share assumption is unverified; treat as Low confidence.

Alongside it in Quality, compliance and lifecycle regulatory services

// Sell into Medtech & IVD quality-system implementation and compliance audit support

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.